Study on dose-effect relationship and intelligent model of muscle relaxant in infants

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057620

Enrollment

Unknown

Registered

2022-03-15

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hirschsprung's disease

Interventions

None listed

Eligibility

Sex/Gender

All

Age

0.1 Years to 3 Years

Inclusion criteria

Inclusion criteria: 1. Age from 3 days to 3 years (including 3 years), no gender limitation; 2. Subjects diagnosed with hirschsprung's disease undergoing radical hirschsprung's disease surgery; 3. Full-term infants with normal nutritional development; 4. American Society of Anesthesiologists (ASA) Level I-II 5. Child-PLUG Score Level A; 6. Not allergic to narcotic drugs.

Exclusion criteria

Exclusion criteria: 1. Any abnormal electrocardiogram (ECG) examination; 2. Any abnormal echocardiographic cardiac examination; 3. Premature infants, low weight children, and malnourished children; 4. No other underlying diseases; 5. Allergic to narcotic drugs.

Design outcomes

Primary

Measure	Time frame
Blood drug concentration;Train of four stimulation;	—

Countries

China

Contacts

Public ContactZhouyang Wu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

wzy6638@sina.com+86 18971335881

Outcome results